Skip to main content
STAASTAAR Surgical CompanyHold6.4·$23.51+1.91%

STAAR Surgical (STAA) Q2 2026 earnings — TrendMatrix coverage

BEAT+9.7% vs estimateEPS $0.25 vs $0.23 estVerdict Buy (Wait)Hold

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure

Event detail · Q2 2026

Key numbers

Reported EPS
$0.25
Estimate
$0.23
Surprise
+9.7%
Revenue (period 2026-07-03)
$93.5M
Score at report (before → after)
6.56.7/10

Revenue source: xbrl.

Report record · Q2 2026

How the report landed

STAAR Surgical (STAA) beat the $0.23 estimate with diluted EPS of $0.25 — a clear 9.7% upside surprise. TrendMatrix's engine moved from Buy (Wait) (6.5/10) to Hold at 6.7/10 after the report.

Around the report

Coverage in the report window

  • UBS Maintains Sell on Staar Surgical, Lowers Price Target to $19benzinga, 2026-08-13
Current read · as of 2026-08-23

Where TrendMatrix's rating stands now

TrendMatrix currently rates STAA Hold at 6.4/10.

3 of the last 4 quarters beat the estimate; this quarter's +9.7% surprise compares with a +62.4% four-quarter average. Next scheduled report: 2026-11-11.

What supports the rating

  • Strong earnings beat streak (3/4)
  • Strong growth profile

What argues against it

  • Concentration risk — Geographic: outside the United States (91.0%)
  • Concentration risk — Product: ICLs (100.0%)
  • Thin upside margin: 4.9%

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$23.51
Price target
$24.27
Stop
$21.52
Upside to target
+3.2%
Reward-to-risk
0.4:1

The stock trades at 289.3× trailing but 22.6× forward earnings — consensus estimates already build in a substantial earnings recovery.

Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.

Healthcare context

STAA at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Medical Instruments & Supplies
Market cap
$1.16B
P/E (fwd)
22.6
P/E (ttm)
289.3
52-week range
$15.59$35.87
Off 52-week high
34.5%
RSI (14)
44
Volume vs avg
0.66×
Score today
6.4/10

Earnings figures are sourced from TrendMatrix’s pipeline (EPS: existing earnings extraction; revenue: SEC XBRL company facts where available, yfinance-provisional otherwise). Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home Stocks STAA Earnings Q2 2026 earnings